A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
for Neovascular Age-related Macular Degeneration
29 locations incl. Long Beach
Sponsor: Amgen
Sex: All·Age: 50+
Code: NCT07614776·Phase 3·Recruiting·Listed May 29, 2026